A new era of nuclear medicine brings hope for millions of cancer patients.
Global nuclear medicine leader Curium is entering a transformative phase in cancer treatment. The company is advancing radioligand therapy, an innovative technique that delivers radiation directly to cancer cells while protecting surrounding healthy tissue.
Early clinical results are promising. Patients have shown longer survival, less pain, and an improved quality of life.
How Radioligand Therapy Works
Radioligand therapy attaches a radioactive isotope to a molecule designed to find and bind to tumour cells. Once the molecule locks onto the cancer cell, it releases radiation that destroys it from within.
Unlike chemotherapy or external radiation, this approach targets tumours precisely. It reduces the toxic impact on the rest of the body and limits side effects.
Curium is using this precision technology to tackle advanced prostate cancer, responsible for almost 400,000 deaths each year. The company is also exploring earlier use of the treatment alongside standard therapies such as surgery and chemotherapy.
A Vision to Treat 80% of Cancers
CEO Renaud Dehareng leads this bold vision.
“Our mission is to find innovative ways to diagnose and treat cancer to improve patients’ lives,” he says.
Curium reinvests profits from its established diagnostics business into research and development. Its growing pipeline includes targeted radionuclide therapies for specific tumour types.
Dehareng’s goal is ambitious: to make radioligand therapy available for up to 80% of cancers within 15 years.
From Proton to Patient
Curium has decades of experience in nuclear medicine. The company supplies isotopes and radiopharmaceuticals for millions of PET and SPECT scans every year. Now, that same expertise supports its therapeutic expansion.
Its production network spans continents, enabling Curium to deliver treatments quickly. This scale matters, as radioligand therapies have a short shelf life and must reach patients rapidly.
Curium calls this approach “from proton to patient” — a model that combines innovation, manufacturing, and global distribution.
Analysts predict that the radiopharmaceutical market could exceed €35 billion by 2033. With its infrastructure and expertise, Curium is positioned to play a central role in this growing field.
Momentum from the Medical Community
Regulators and clinicians are already supporting this new wave of targeted treatments. Hospitals across Europe and the US are showing increased interest as early data continues to impress.
“No single treatment will replace surgery, chemotherapy, or radiotherapy,” says Dehareng. “But radioligand therapy could become one of the biggest advances in oncology in decades. It offers patients more time — and fewer side effects.”
This approach aligns with a global shift toward personalised medicine. Each patient’s tumour can be targeted with precision, reducing unnecessary harm and improving outcomes.